I Charles Pathirana

Title: I Charles Pathirana: Innovator in Progesterone Receptor Modulation

Introduction

I Charles Pathirana is a notable inventor based in San Diego, CA. He has made significant contributions to the field of pharmacology, particularly in the development of non-steroidal compounds that interact with progesterone receptors. His innovative work has implications for therapeutic applications in hormone-related treatments.

Latest Patents

Pathirana holds a patent for a "Non-steroid progesterone receptor agonist and antagonist and compounds." This patent discloses non-steroidal compounds that serve as high-affinity, high-specificity ligands for progesterone receptors. The compounds include synthetic derivatives of cyclocymopol and its diastereomers. Notably, the patent describes the (3R)-cyclocymopol monomethyl ether, which acts as a progesterone receptor antagonist, and the (3S)-cyclocymopol monomethyl ether, which functions as a progesterone receptor agonist. The patent also outlines methods for utilizing these compounds to modulate processes mediated by progesterone receptors and for treating patients who require progesterone receptor agonist or antagonist therapy. Pathirana has 1 patent to his name.

Career Highlights

Throughout his career, Pathirana has worked with esteemed institutions, including the University of California and Ligand Pharmaceuticals, Inc. His work has been pivotal in advancing the understanding of progesterone receptor interactions and their therapeutic potential.

Collaborations

Pathirana has collaborated with notable professionals in his field, including William H. Fenical and Lawrence G. Hamann. These collaborations have contributed to the depth and breadth of his research and innovations.

Conclusion

I Charles Pathirana's contributions to the field of progesterone receptor modulation highlight his role as an innovative inventor. His work continues to influence therapeutic strategies in hormone-related treatments.